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ABSTRACT 12 
The relative bioavailability of arsenic, antimony, cadmium and lead for the ingestion pathway was 13 
measured in 16 soils contaminated by either smelting or mining activities using a juvenile swine 14 
model. The soils contained 18 to 25000 mg kg-1 As, 18 to 60000 mg kg-1 Sb, 20 to 184 mg kg-1 Cd 15 
and 1460 to 40214 mg kg-1 Pb.  The bioavailability in the soils was measured in kidney, liver, bone 16 
and urine relative to soluble salts of the four elements. The variety of soil types, the total 17 
concentrations of the elements and the range of bioavailabilities found were considered to be 18 
suitable for calibrating the in vitro Unified BARGE bioaccessibility method. The bioaccessibility 19 
test has been developed by the BioAccessibility Research Group of Europe (BARGE) and is known 20 
as the Unified BARGE Method (UBM).  The study looked at 4 end points from the in vivo 21 
measurements and two compartments in the in vitro study (‘stomach’ and ‘stomach & intestine’). 22 
Using benchmark criteria for assessing the ‘fitness for purpose’ of the UBM bioaccessibility data to 23 
act as an analogue for bioavailability in risk assessment, the study shows that the UBM met criteria 24 
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on repeatability (median relative standard deviation value < 10%) and the regression statistics 25 
(slope 0.8 to 1.2 and r-square >0.6) for As, Cd and Pb. The data suggest a small bias in the UBM 26 
relative bioaccessibility of As and Pb compared to the relative bioavailability measurements of 3% 27 
and 5% respectively. Sb did not meet the criteria due to the small range of bioaccessibility values 28 
found in the samples.  29 
Keywords: Relative Bioavailability, Arsenic, Cadmium, Lead, Antimony, swine model, 30 
bioaccessibility, soil 31 
32 
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INTRODUCTION 37 
Soils contaminated by potentially harmful elements (PHE), such as cadmium (Cd) and lead (Pb) constitute a 38 
potential risk to human health [1, 2]. Other important PHE are the metalloids arsenic (As) and antimony 39 
(Sb).  These elements are distributed through the environment as a result of both natural and 40 
anthropogenic activities such as mining or smelting [3, 4]. Once released into the environment, soils 41 
often serve as a sink for these PHE and the question of human exposure to such elements must then 42 
be addressed. Indeed, As and Sb were recognized as priority pollutants by the US-EPA in 1979, 43 
because of their contribution to cancer development, genotoxicity and apoptosis in mammals [5, 6].  44 
Ingestion is one of the major routes of soil exposure to these contaminants by children. [7-9]. 45 
Exposure is currently assessed using the total soil concentration of individual contaminants. 46 
However, several in vivo studies, using diverse animals such as monkeys, juvenile swine, rabbits 47 
and rodents, have demonstrated that only a fraction of a contaminant, the bioavailable fraction, is 48 
absorbed following oral administration [10-16]. In the literature, the juvenile swine model is 49 
considered to be a good physiological model for gastrointestinal (GI) absorption of contaminants in 50 
children [17]. Recently, in the particular case of As, the swine model was described as being a 51 
particularly accurate representation of human physiology [18]. Bioavailability is defined as the 52 
fraction of an ingested dose that crosses the GI epithelium and becomes available for distribution to 53 
internal target tissues and organs [19, 20]. Absolute bioavailability is directly determined in the 54 
blood plasma and consists in comparing the concentration in the plasma following an intra-venous 55 
injection and an oral administration [13, 19-21]. However, this method is not easily achievable due 56 
to both experimental issues linked to blood sampling and to analytical limitations such as the 57 
generally low concentrations in the blood compared to quantification limits [22]. Thus, in vivo 58 
protocols have been developed to estimate the relative bioavailability (RBA). This is measured as 59 
the uptake of the contaminant in the target organ from the soil matrix relative to the uptake from a 60 
readily soluble salt of the contaminant (reference matrix) [16, 19, 23]. Several studies have 61 
established that either absolute or relative bioavailability of soil metals were below 1 and are 62 
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dependent on soil edaphic properties (e.g. pH, granulometry) and the soil metal speciation [10, 15, 63 
16, 20]. Consequently, human exposure to soil bound contaminants can be overestimated when the 64 
bioavailability is not considered.  The BioAccessibility Research Group of Europe (BARGE) [24] 65 
have developed an in vitro test, the Unified BARGE Method (UBM), to measure the 66 
bioaccessibility of soil contaminants. So far, a preliminary study [25] suggests that the UBM 67 
bioaccessibility data are correlated to in vivo bioavailability data. However, problems with the soils 68 
used in the study (they contained unusually high content of mining slag) require that a more 69 
rigorous and robust validation of the UBM against in vivo data is essential before the UBM can be 70 
used as a routine tool in risk assessment. The aim of this study is to measure the relative 71 
bioavailability of As, Sb, Cd and Pb in soil using a juvenile swine model, for 16 soils contaminated 72 
by either smelting or mining activities and to use the data from these soils to validate the UBM.  So 73 
far, most other studies have focused on a single element and not on multi-contaminated soil samples 74 
which are commonly found together on contaminated lands. Moreover, no study has been carried 75 
out on the human bioavailability of Sb.  76 
The first part of this study is to measure the relative bioavailability (RBA) of As, Cd, Pb and Sb 77 
from selected contaminated soils using a swine model. Whilst this data gives some insight into the 78 
fraction of inorganic contaminants that is bioavailable, risk assessors need specific information 79 
about each site being studied.  However, due to the high number of sites with soils contaminated 80 
with As, Cd, Pb and/or Sb, it is not possible to determine the bioavailability in each case, as in vivo 81 
experiments are time-consuming, costly and ethically problematic [19]. To address this, numerous 82 
in vitro protocols have been designed to simulate the human digestive processes using artificial 83 
digestive fluids to determine the bioaccessible fraction of contaminants, i.e. the fraction of the PHE 84 
content of the soil released into solution within the GI system which is then potentially available for 85 
absorption, and have been comprehensively reviewed [26, 27]. The underlying hypothesis is that the 86 
bioaccessibility reflects the bioavailability of a soil contaminant and allows for a more accurate 87 
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estimation of the exposure concentration compared to the total soil concentration of the 88 
contaminant. However, from one in vitro test to another, the bioaccessibility can greatly vary for the 89 
same soil sample [28-31]. Consequently, before such assays can act as a surrogate measurement for 90 
relative metals bioavailability, a correlation between in vitro bioaccessibility and in vivo 91 
bioavailability is necessary, for both regulatory and scientific acceptance. The objective of this 92 
research was to carry out a more robust validation study to demonstrate the physiological accuracy 93 
of the UBM for As, Cd, Pb and Sb. 94 
MATERIALS AND METHODS 95 
Soil collection sample preparation and chemical analysis 96 
Full details of the soil collection, sample preparation and chemical analysis of the soil and swine 97 
samples are given in the supporting information. 98 
Determination of in vivo relative bioavailability 99 
The RBA of As, Pb, Cd and Sb were determined for each soil sample using readily soluble forms of 100 
the contaminants, sodium arsenate (NaH2AsO4), Pb-acetate ((CH3COO)2Pb), Cd-chloride (CdCl2) 101 
and potassium antimonate (KSbO3)).  These reference matrices were chosen to estimate the RBA as 102 
they had been used in previous RBA studies for As and Sb [14, 21, 32] and Pb and Cd [11, 33]. 103 
The RBA of all elements studied were determined in four end points: urine; bone (metacarpal IV); 104 
liver; and kidney. The number of swine is 15 for the reference groups and 9 for the soil groups, 105 
leading to a total of 159 swine. Full details of the methodology are given in the supporting 106 
information. 107 
Dose Response Curve and RBA calculation  108 
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For a given contaminant, each soil and reference matrix, a dose-response curve was established by 109 
plotting the concentration in the target end point as a function of the administered dose. Before 110 
calculating the RBA, three conditions needed to be verified [34]: 111 
 That the response was linear for the soil and reference dose;  112 
 That the intercepts for all of the lines were equal (i.e. had a common intercept); 113 
 That the response at the zero level (called “blanks” i.e. the 3g of moistened feed without any 114 
soil or reference dose; for details see the SI) was less than or equal to the common intercept 115 
value of the lines. 116 
These assumptions were verified using SAS 9.1 (SAS Institute, Cary, NC, USA) using a 117 
standard methodology for animal bioavailability studies [34]. 118 
For each linear response, the slope value and the standard deviation were determined for each value. 119 
The RBA was calculated as the ratio of the soil to the reference matrix slope values, when the 120 
difference between the two slope values was significant (P<0.05) [34]. In the case of a non-121 
significant difference between the two slope values, the RBA was assumed to be 100%.  122 
Unified BARGE Method  123 
Bioaccessibility measurements were performed on five replicates of each soil and reference matrix 124 
(Na-arsenate, K-antimoniate, Pb-acetate and Cd-chloride) using the UBM. A full description of the 125 
method is given in the supporting information.  126 
Bioaccessibility calculation 127 
The following equations are used to calculate bioaccessible concentration for the ‘stomach’ and 128 
‘stomach & intestine’ phases and the bioaccessible fraction in the soil.   129 
BAs=Vs × Ce × d /m  i) 130 
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BAs&int=Vs&int × Ce × d / m  ii) 131 
BAFs=100 × BAs /Te  iii) 132 
BAFs&int=100 × BAs&int /Te iv) 133 
 134 
Where: 135 
BAs =Bioaccessible concentration for the ‘stomach’ phase in the soil (mg kg-1) 136 
BAs&int =Bioaccessible concentration for the ‘stomach & intestine’ phase in the soil (mg kg-1) 137 
Vs = Volume of fluid used in the ‘stomach’ phase extraction including any pH adjustments (mL) 138 
Vs&int = Volume of fluid used in the ‘stomach & intestine’ phase extraction including any pH 139 
adjustments (mL) 140 
Ce = Measured concentration of the contaminant e in the diluted extract solution (mg L-1) 141 
d = Dilution applied to the extract solution prior to analysis 142 
m = Mass of soil used in the extraction (g) 143 
Te = Total concentration of the contaminant e in the soil (mg kg-1) 144 
BAFs = The ‘stomach’ phase bioaccessible fraction (%) 145 
BAFs&int = The ‘stomach & intestine’ phase bioaccessible fraction (%) 146 
Statistical analysis 147 
The statistical analysis was carried out using the R programming language [35].  The regression 148 
analysis was carried out using Siegels’s repeated medians method [36] as implemented in the 149 
“mblm” R statistical analysis package [37]. 150 
RESULTS AND DISCUSSION  151 
Animal health over the time frame of the experiment 152 
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During the 14 runs of the in vivo experiments, the animals exposed to As, Cd, Pb and Sb contamination 153 
remained healthy, continued to consume their feed, grew normally and none died. The mean BW of the 154 
swine at the beginning of experiment was 9.5 ± 1.2 kg (n=168 swine) and, at the end 16.8 ± 1.5 kg (n=168 155 
swine). Moreover, there was no correlation between the several exposure doses for each contaminant and the 156 
final BW of each swine (r2 = 0.12, p>0.05, n=168). Similarly, for the different target end point (kidney, liver 157 
and metacarple IV), there was no impact of exposure doses on their final weight.  158 
Dose-response curves 159 
To ensure comparability between the dose response curves for the soluble salt and for the soils the 160 
concentration of the soluble salt dose was designed to give a response which encompassed those 161 
obtained for each element in each soil for each end point (see Figures 1 and 3)   162 
Metals - Cd and Pb 163 
The concentrations of Cd and Pb in the end points resulting from dosing with the reference matrix 164 
were all above quantification limits. For the soils, Pb concentrations were all above the 165 
quantification limits, whereas for Cd some concentrations were below. When the concentrations 166 
were measurable, the dose-response curves for both soils and reference matrix fitted to a linear 167 
model (p <0.05) (example plots in Figure 1) except for soils 8 and 9 for the Pb response in the liver 168 
(Figure 2).  A similar pattern in the dose-response curves (Figure 1) has been previously reported 169 
for both Pb and Cd [11, 16, 33].  170 
UBM validation 24-Jan-11 Version 2 
  10 
 
 171 
 172 
Figure 1 Examples of linear dose-response curves for Cd (kidney) and Pb (liver) 173 
 174 
 175 
Figure 2 Non-linear dose-response curve for Pb in liver 176 
The repeatability of each response was also evaluated by calculating the relative standard deviation 177 
(RSD) n=3 data for each end point. Where RSD is calculated as the mean value divided by the 178 
standard deviation expressed as a percentage) For Pb, the RSD values were the lowest for Pb-179 
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acetate (less than 1%) and the highest for soils F and G (around 20%). For Cd, the RSD values were 180 
lowest for Cd-chloride (less than 1%) and highest for soil 2 (around 30%) 181 
Metalloids – As and Sb 182 
Arsenic was quantified in each end point, giving linear models (p<0.05). For Sb, however, apart 183 
from soils 1 and 2 with high total Sb content (Table S1 of the supporting information), dose 184 
response data could only be obtained for urine. The dose-response curve for this end point fitted a 185 
linear model (p<0.05) (Figure 3). Example dose response curves for both As and Sb are given in 186 
Figure 3. 187 
The repeatability of the response was also evaluated by calculating its RSD for each end point. For 188 
As, the lowest RSD value was obtained for the reference matrix (around 0.6%) and the highest 189 
value was obtained for the soil 7 (70 %). For Sb, the lowest RSD was obtained for urine on the 190 
reference material (less than 1%). The soils ranged from 15% to 50%. This reflects the difficulty of 191 
obtaining reproducible values of Sb concentrations due to the combined effect of relatively low 192 
concentrations (apart from soil 1 and 2) and low bioavailability of this element. 193 
 194 
Figure 3 Examples of linear dose response curves for As and Sb in urine 195 
Relative bioavailability of Pb and Cd 196 
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The Cd and Pb RBA values and associated uncertainties are given in the supporting information 197 
(Table S4).  Cd-RBA could not be calculated for soils 1, 4, 10 and A, C, E in any of the end points 198 
because the concentrations were below the quantification limits. The Pb-RBA could not be 199 
calculated in soils 8 and 9 from the liver results, as the dose-response curves for these end points 200 
were not linear. For soils E and F (kidney, bone and urine) and for soil D (bone and urine) there was 201 
no significant difference between the slopes obtained for the reference matrix and the contaminated 202 
soil for Pb. In these cases, the RBA was 100% meaning that Pb in these soils is as bioavailable as 203 
Pb-acetate for the purposes of oral exposure.  204 
The RBA values were consistent among the end points (Table S2) and were reproducible between 205 
the replicates. This confirms the robustness of the juvenile swine in vivo model to estimate the RBA 206 
of Pb and Cd in contaminated soils. The RBA values are within the range of other juvenile swine 207 
studies with the same soluble reference compounds [11, 15, 16, 33].  208 
Both Pb and the Cd showed a similar range of RBA values with a good coverage of the % RBA 209 
range with minimum to maximum values of 6-100% RBA for Pb and minimum to maximum values 210 
of 9-89% RBA for Cd.  This is a fundamental pre-requisite to use these data in correlation studies 211 
[22, 38].  212 
Relative bioavailability of As and Sb  213 
RBA values for As and Sb estimated from each end point and each soil samples are given in the 214 
supporting information (Table S3). 215 
The RBA for As could not be calculated for any of the target compartments for soils 5, D and E and 216 
the RBA of Sb could not be calculated for soils 3, 5, D and E as the concentrations of the elements 217 
in the end points were below the quantification limits. This reflects a strong decrease of both As and 218 
Sb bioavailability compared to the reference matrix. 219 
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For Sb, the RBA could be calculated from kidney, liver and bone only for soils 1 and 2, with the 220 
highest Sb content (Table S1). For these two soils, the RBA values of Sb were consistently low 221 
among the target end points, (<4%). For the other soils, the RBA was measured only in urine and 222 
did not exceed 11%. For As the average minimum to maximum % RBA range was 3-74%. 223 
The results obtained for Sb are critical for the overall objective of this study as a fundamental 224 
criterion of such a validation study is to have values of RBA evenly spread between the minimum 225 
and maximum interval for the overall data set [22, 38]. This is probably due to a particularly low 226 
overall bioavailability of Sb irrespective of the soil properties. Unfortunately, no previous study on 227 
Sb has been published in the literature for comparison with the data produced here. The low average 228 
% RBA range for Sb (2-6%) is unlikely to be suitable for validation of in vitro bioaccessibility tests.   229 
For As (Table S3), however, the RBA values are evenly dispersed over the RBA range (3-100%). 230 
Moreover, the RBA values are similar to the range of values obtained by several authors on soils 231 
contaminated by both mining and smelting activities. For instance Rodriguez et al [39] reported 232 
values ranging between 3% and 43%, and Juhasz et al [13] 7%-75%.  A major factor that explains 233 
the variation observed among the soil samples is the solid phase distribution of As within the soil 234 
which differs according to soils type and physico-chemical properties [13]. 235 
Bioaccessibility of As, Sb Cd and Pb in the reference matrix  236 
The BAF of each PHE in the soluble salts used to measure the in vivo RBA were determined using 237 
the UBM procedure (As in Na-arsenate, Sb in K-antimonate, Pb in Pb-acetate and Cd in Cd-238 
chloride). These soluble salts were spiked to give a 1 mg kg-1 concentration of each of the elements 239 
in the final ‘stomach’ or ‘stomach & intestine’ extract. This allowed the calculation of the relative 240 
bioaccessibility (RBAc), to allow a direct comparison with the RBA values. For the cations in the 241 
‘stomach’ phase, the BAF values were 99 ± 2% and 98 ± 3% for Pb-acetate and Cd-chloride, 242 
respectively. For the anions the As BAF was 95 ± 3% and the Sb BAF was 93 ± 5%.  This showed 243 
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that all four elements were either indistinguishable or within 2% of being 100% bioaccessible for 244 
the reference compounds in this compartment. In contrast, in the ‘stomach & intestine’ phase the 245 
cations had much reduced BAFs with Pb and Cd giving values of 66 ± 3% and 68 ± 3% with As 246 
and Sb BAFs of 92 ± 4% and 90 ± 2% respectively. The lower recoveries of Pb and Cd can be 247 
explained by the fact that the behaviour of these elements is strongly pH dependent.  In the higher 248 
pH environment of the ‘stomach & intestine’ phase these metals can precipitate from solution, be 249 
reabsorbed onto the soil and complexed by pepsin [40, 41]. This is not observed in the case of 250 
elements (such as As and Sb) that form anions in solution and is consistent with previous studies 251 
[42]. 252 
Relative bioaccessibilities of As, Cd, Pb and Sb in the contaminated soils 253 
The RBAc was estimated as the ratio of the soil bioaccessibility to the reference matrix 254 
bioaccessibility (%) for each phase and each element and are tabulated in the supporting 255 
information (Tables S4 and S5). When individual t statistic 95% confidence intervals were 256 
calculated for Cd and Pb the data indicated that, in general, the ‘stomach & intestine’ 257 
bioaccessibility is not significantly different from the ‘stomach’ phase bioaccessibility except for 258 
soils 5, 7, C and E for Pb and soil 5 for Cd where the ‘stomach phase’ gives a significantly higher 259 
bioaccessibility. For Cd and Pb the ‘stomach phase’ bioaccessibility is usually significantly higher 260 
than the GI bioaccessibility for these elements [29]. This is because of the behaviour of Pb and Cd 261 
is strongly pH dependent with lower solubility in the higher pH environment of the GI 262 
compartment.  In this instance, however, the bioaccessibility results have been calculated relative to 263 
the bioaccessibility of the soluble salts (Pb-acetate and Cd chloride) which also show reduced 264 
solubility at high pH. Taking measurement relative to the soluble salts therefore corrects for the 265 
lower absolute Pb and Cd bioaccessibilities in the ‘stomach & intestine’ phase. 266 
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For the mining soils, RBAc of Pb and Cd ranged from 9% to 75% and from 7% to 70%, 267 
respectively. For the smelting soils, the relative Pb bioaccessibility ranged from 40% to 90% and 268 
the relative Cd bioaccessibility ranged from 28% to 87%. These values are in similar to values 269 
reported in the literature [16, 42, 43].  270 
For As and Sb no difference was observed between the two phases, apart from soil 2 for As. The 271 
values of As RBAc ranged between 3% and 11% for the mining soils and between 11% and 74% in 272 
the smelting soils. Thus, it seems that the bioaccessibility seems to be influenced by the source of 273 
contamination, being higher in the smelting contaminated soils. This might be due to the difference 274 
in the solid phase distribution of As within the soil constituents between the mining and smelting 275 
soils. In the mining soils As appears to be associated with iron oxides and sulphide minerals and 276 
consequently has a low bioaccessibility [44-46]. 277 
For Sb, RBAc was always 20% lower than RBA and no significant difference was observed 278 
between mining and smelting soils. This overall low bioaccessibility might be explained by the 279 
association of Sb and soil bearing phases like iron oxy-hydroxides, sulphides and refractory soil 280 
constituents [47-50] that are not easily dissolved by the artificial digestive solutions used during the 281 
UBM. 282 
Correlation between relative bioavailabilities and bioaccessibilities 283 
For a given contaminant, the bioavailability theoretically results from three steps:  284 
 the dissolution of the contaminant in the lumen that is determined as the bioaccessibility 285 
(BAc); 286 
 the absorption of the contaminant through the GI membrane (ABS); 287 
 the metabolism of the contaminant within the internal media (this is assumed to be 288 
negligible for trace elements) [42]. 289 
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The RBA can be determined as from the following formula [42]: 290 
RBA = RBAc x ABSR v) 291 
Where: 292 
 RBAc: the relative bioaccessibility of the contaminant, i.e. the soil:reference matrix 293 
bioaccessibility of the contaminant 294 
 ABSR: the relative absorption of the contaminant. 295 
If the RBA is properly reflected by the RBAc, then the bioaccessibility should be the limiting factor 296 
[38, 42]. As such, ABSR should be close to 1, meaning that the absorption step is independent from 297 
the initial form of the contaminant that is ingested. In this case, RBA should be equal to RBAc, i.e. 298 
the slope of the regression between RBA and RBAc should be equal to 1. The slopes of the 299 
regression between RBA and RBAc were calculated for each target compartment and for the two 300 
phases of the UBM.  301 
 302 
Regression of the UBM relative bioaccessibility against in-vivo relative bioavailability 303 
An earlier study comparing UBM data against in vivo bioavailability on test soils, [25] set out a 304 
series of benchmark criteria that should be met by the in vitro and in vivo data and any subsequent 305 
mathematical regression relationship in order for the in vitro methodology to supply “fit for purpose 306 
data” for risk assessments.  The first criterion is that the median repeatability on the bioavailability 307 
data should be better than 20% RSD.  308 
 309 
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Figures S1 and S2 in the supplementary information show boxplot summaries of the repeatability 310 
(RSD of the RBA replicate measurements) of the bioavailability the four end points of the sixteen 311 
soils for As, Cd and Pb.  312 
Sb has not been included since the bioavailability data were of not of sufficient quality to carry out 313 
a correlation with bioaccessibility data.   314 
For both Cd and Pb the median repeatability values are well within the benchmark (Figure S1 in the 315 
supplementary information). The repeatability values for As values are higher for all end points 316 
with the kidney end point benchmark value of 20.6% and the liver end point only just above at 317 
22.5% (Figure S1). Although not strictly met, it is considered that a median value of 20.6% vs the 318 
ideal criteria of 20% for the two compartments was considered acceptable for the kidney end point 319 
and should not to compromise the use of the UBM for As in a soil risk assessment. 320 
The second benchmark relates to the bioaccessibility repeatability (within-laboratory variability) 321 
and reproducibility (between-laboratory variability). The former should have a median value of 322 
10% RSD and the latter a median value of 20% RSD.  323 
Only within-laboratory data are available for this study so, only the repeatability can be tested.  324 
Figure S2 in the supporting information shows boxplots of the repeatability (RSD of the RBAc 325 
replicate measurements) for each of the elements studied.   326 
 327 
In this case, Sb values have been included as since robust results were obtained for this element 328 
from the UBM bioaccessibility test. Figure S2 shows that the median repeatability values for the 329 
UBM are all below the 10% benchmark for all elements in both the ‘stomach’ and ‘stomach & 330 
intestine’ compartments.  The median reproducibility values are very similar for each compartment 331 
although the spread of values is consistently higher in the ‘stomach & intestine’ compartment.  332 
Median repeatability values are all very similar at c. 5-7% RSD but As shows higher variability in 333 
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values compared the other three elements. This is a similar pattern to the in vivo data shown in 334 
Figure S1. 335 
The next set of benchmark criteria relate to the statistical parameters associated with linear 336 
regression fits to the relationship between RBA and RBAc. Since there is significant error (median 337 
RSD of up to 30% for bioavailability and 8% for bioaccessibility, Figures S1 and S2) on both the 338 
bioaccessibility and bioavailability data (Tables S2-S5), ordinary linear regression is not appropriate 339 
as it assumes that there are errors only on the ‘y’ co-ordinate.  In this study a repeated medians 340 
approach [36] is used, which makes no assumptions about errors and is robust to outliers. The 341 
method has been applied using a monte-carlo approach varying each point over a normal 342 
distribution described by its mean value and standard deviation.  The advantage of this is that it 343 
produces a distribution of values for the descriptive statistics for the regression (intercept, slope and 344 
r square) so that 95% confidence intervals can be calculated and can then be judged against a 345 
benchmark value. Wragg et al [25] suggested that the benchmark criteria should be: 346 
i) The intercept is not significantly different from 0; 347 
ii) The slope should be between 0.8 and 1.2; 348 
iii) The r square value (measure of the scatter around the line) should be greater than 0.6. 349 
Using this methodology, the linear regressions of relative bioaccessibility against relative 350 
bioavailability were calculated using the data from the supporting information (Tables S2-S5). All 351 
data were included in the calculation apart from the RBA values which could not be calculated 352 
because the absolute concentration of the elements in the target organ was below detection limit or 353 
because the dose response curves were not linear. Summary statistics, in the form of a mean value 354 
of the intercept, slope or r square value and their associated 95% confidence intervals for each 355 
element regression for each end point and each stomach compartment are shown in Figures 4-6.   356 
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 357 
Figure 4 Summary of the RBA vs RBAc regression statistics for the four end points for As. Black 358 
squares show data for the ‘stomach’ phase and white triangles for the ‘stomach & intestine’ phase. 359 
Error bars represent 95% confidence limits dotted lines show benchmark values. 360 
 361 
Examination of Figures 4 to 6 shows that, for all elements in all endpoints the slope and the r square 362 
values all meet the benchmark criteria.  For Cd (Figure 5) the intercepts only shows one incidence 363 
out of eight where the intercept is positive (bone in the stomach compartment). For both As and Pb 364 
(Figures 4 and 6), however, there are five incidences out of eight where the intercepts are shown to 365 
be >0. This suggests there is a small bias in the RBAc measurement for these elements compared to 366 
the RBA (3% RBAc for As and 5% RBAc for Pb averaged over all endpoints and compartments). 367 
The plots also confirm that there is no significant difference between the ‘stomach’ and ‘stomach & 368 
intestine’ compartments for all three elements and all four end points.  369 
 370 
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Figure 5 Summary of the RBA vs RBAc regression statistics for the four end points for Cd. Black 372 
squares show data for the ‘stomach’ phase and white triangles for the ‘stomach & intestine’ phase. 373 
Error bars represent 95% confidence limits, dotted lines show benchmark values 374 
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 375 
Figure 6 Figure 3 Summary of the RBA vs RBAc regression statistics for the four end points for Pb. 376 
Black squares show data for the ‘stomach’ phase and white triangles for the ‘stomach & intestine’ 377 
phase. Error bars represent 95% confidence limits, dotted lines show benchmark values. 378 
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 380 
Figure 7 correlation plots for RBAc against RBA for (a) Pb and (b) Cd for the ‘stomach’ and 381 
‘stomach & intestine’ phases for the kidney endpoint. Bold dashed dotted line is the line of 382 
equivalence, dashed lines are the 95% confidence intervals and the solid lines is the best line of fit 383 
 384 
For the four target end points selected for this study (kidney, urine, bone and liver), the r square 385 
value for the RBAc and RBA regressions were all significantly different from 0 both for the 386 
‘stomach’ and the ‘stomach & intestine’ phases.  Since the slopes of regressions are all close to 1, it 387 
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appears that the RBAc is actually the limiting factor of the RBA. This confirms the ability of the 388 
UBM test to assess the bioaccessibilities of As, Cd and Pb in the contaminated soils studied. The 389 
bioaccessibility as measured by UBM better reflects the external exposure to soil contaminants 390 
following an oral ingestion than the total concentration. 391 
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 392 
Figure 8 correlation plots for RBAc against RBA for (c) As and (d) Sb for the ‘stomach’ and 393 
‘stomach & intestine’ phases for the urine end point. Bold dashed dotted line is the line of 394 
equivalence, dashed lines are the 95% confidence intervals and the solid line is the best line of fit. 395 
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Figures 7 and 8 show example RBAc plots versus RBA showing how the fitted regressions are very 396 
close to the ideal 1:1 relationship for As (Figure 8 a and b), Cd and Pb (Figure 7) but with evidence 397 
for small positive intercepts in As in the ‘stomach’ phase (Figure 8 a) and Pb in the ‘stomach’ phase 398 
(Figure 7 a) . For Sb, however, the low bioavailabilities and bioaccessibilities that were measured 399 
for the soils sampled in this work meant that the correlations could only be studied in the 0%-20% 400 
area. In these conditions, the UBM test could not be validated for Sb due to a lack of statistical 401 
significance which is clearly illustrated in Figure 8 c) and d). The 95% confidence interval in the 402 
line of best fit is far too wide to provide a useful relationship between RBAc and RBA, which could 403 
be used by a risk assessor. 404 
The juvenile swine model has been shown to produce RBA values that are consistent within the 405 
target end points for As, Cd and Pb for the 16 soils studied. The variety of soil types, the range of 406 
total element values are representative of the total concentrations of these elements that would 407 
normally be considered for bioaccessibility testing [25].  The RBA values for all three of these 408 
elements covered at least 70% of the RBA range making them highly suitable for calibrating in 409 
vitro testing protocols.  410 
For Sb, however, the RBA values were approximately 10% or less for all soils and it was difficult 411 
to measure the amount of Sb absorbed into the target end points, apart from urine, for all but soils 1 412 
and 2 which are grossly contaminated with Sb (>50000 mg kg-1, Table S1).  The small RBA range 413 
covered will not make this data set suitable for calibrating Sb bioaccessibility measurements from in 414 
vitro testing methods. 415 
Whilst it would be impossible to show that the UBM has been validated for all soil types, this study 416 
has concentrated on soils with anthropogenic contamination (combined with their natural PHE 417 
content) which are likely candidates for human health risk assessment.  The study has used soils 418 
from a variety of spatial locations with a range of physicochemical properties and which exhibit a 419 
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good range of PHE bioaccessibilities. These results provide strong evidence that, through a 420 
pragmatic choice of soils, the UBM provides a robust tool for use in risk assessment of As, Cd and 421 
Pb. The study suggests the ‘stomach’ compartment alone is a good analogue of in vivo 422 
bioaccessibility but this need to be confirmed by use of the method on a wider variety of soils.    423 
This study has addressed many of the issues arising from a preliminary inter-laboratory trial of the 424 
UBM [25] showing that a specifically designed in vivo study with soils relevant to European 425 
conditions along with better control on pH in the ‘stomach’ phase that the UBM produces 426 
bioaccessibility data that is a very good analogue of juvenile swine bioavailability measurements 427 
for As, Cd and Pb. The one point that this study has not yet addressed is the inter-laboratory 428 
reproducibility that was problematic in the study of Wragg et al [25].  A further follow up study on 429 
inter-laboratory performance is required to provide the last piece of evidence that the method can be 430 
used as a routine test in risk assessment studies. 431 
Supporting Information Available 432 
The supporting information contains details of the procedures used to determine the bioavailability 433 
and bioaccessibility of the PHEs and the methods used for the preparation, analysis and quality 434 
control of the PHEs in the soil and swine samples.  In addition, tabulations of the soil properties and 435 
the bioavailability of the bioaccessibility of the PHE in each of the soils tested are provided along 436 
with box and whisker plots of the repeatability of the bioavailability and bioaccessibility 437 
measurements.  This information is available free of charge via the Internet at http://pubs.acs.org. 438 
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